Project Grant K08HL173620
Award Date
8/15/24
Completion Date
7/31/29
Dollars Obligated
$165K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Philadelphia, PA 19104, USA
Similar Awards
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research to investigate the role of the VPS34 protein in the development and progression of pulmonary arterial hypertension (PAH). The $491,056.01 award, effective May 20, 2025 through April 30, 2028, aims to examine the regulation and function of VPS34 in PAH, determine its impact on proliferation and survival of pulmonary artery...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under CFDA 93.837 - Cardiovascular Diseases Research provides $596,809 to Emory University to conduct research on the role of the mitochondrial protein MitoNEET in pulmonary hypertension (PH). The research aims to elucidate how MitoNEET regulates pulmonary artery smooth muscle cell function and mitochondrial bioenergetics, and to evaluate the potential of MitoNEET ligands as novel therapies for group 3 PH,...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $167,940 Project Grant (CFDA 93.837 - Cardiovascular Diseases Research) to The Children's Hospital Corporation (doing business as Boston Children's Hospital) with a project period from Sep 20, 2024 to Aug 31, 2029. The grant aims to develop a novel mouse model of flow-induced pulmonary hypertension (PH) that better represents the physiological conditions observed in patients with congenital heart disease. Additionally, the project...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $122,788 Project Grant under the Cardiovascular Diseases Research (CFDA 93.837) program to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), with a project period from September 15, 2024 to June 30, 2026. The goal of this project is to establish a pharmacokinetic model for absolute quantification of pulmonary perfusion and microvascular parameters, and validate this model in large animal...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $1,564,220 Project Grant (CFDA 93.837 - Cardiovascular Diseases Research) to The Trustees of the University of Pennsylvania, doing business as Clinical Practices of the University of Pennsylvania, on Sep 17, 2024. The grant funds the development of an imaging-compatible pre-clinical ex vivo lung perfusion (EVLP) system to obtain structural, functional, and metabolic biomarkers of donor lung health. The project aims to use these...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research (CFDA 93.837) program provides $522,794 to the University of Illinois to conduct research on the role of the voltage-gated proton channel HV1 in the development of pulmonary hypertension. The project aims to use transgenic mice and in vivo approaches to delineate HV1's contributions to pulmonary hypertension pathogenesis, examine the molecular mechanisms, and...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $715,161 Project Grant (CFDA 93.837 - Cardiovascular Diseases Research) to the Trustees of Indiana University, doing business as Indiana University Indianapolis (IU Indianapolis), to conduct research on the epigenetic regulation of pulmonary smooth muscle cell remodeling in pulmonary hypertension. The research aims to elucidate the molecular mechanisms by which the sphingosine kinase 2 (SPHK2) enzyme contributes to vascular...
The National Heart Lung and Blood Institute (NHLBI) awarded a $111,626 Project Grant (CFDA 93.837 - Cardiovascular Diseases Research) to the University of Colorado-Denver to investigate ways to target macrophage populations and attenuate pulmonary hypertension associated with sickle cell disease. The 2-year project aims to determine if modifying iron release from the ferroportin transporter can alter CD169+ macrophage and adaptive immune cell quantities, phenotypes, and oxidative status (Aim 1);...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $1,524,759 to Baylor College of Medicine to conduct research on the pathophysiology of vascular remodeling in pulmonary hypertension, particularly in the context of interstitial lung disease (ILD). The 4-year project aims to: 1) define the transcriptional regulation of the bone morphogenetic protein (BMP)-binding endothelial regulator...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $657,308 to The Children's Hospital of Philadelphia (CHOP) to conduct research on the CXCL12 signaling axis and its role in pulmonary arterial heterogeneity, development, and disease. The key objectives of this 12-month project are to: 1) define the spatiotemporal role of CXCL12 signaling in pulmonary vascular development, 2)...